Exscientia

#MyCompany

We are delighted to announce that we have reached an agreement to acquire the full rights to our precision-designed oral CDK7 inhibitor, GTAEXS617 (‘617), from our partner, GT Apeiron.   ‘617 is currently in the monotherapy dose escalation part of the Phase 1/2 ELUCIDATE trial with data remaining on track to read out in the second half of this year.   This agreement maximises our upside potential for '617  David Hallett, Ph.D., our interim CEO and Chief Scientific Officer: “We are excited to have full ownership of this potentially transformative asset. CDK inhibitors are a major class of oncology drugs, and we believe our highly differentiated compound has the potential to greatly expand impact for patients and exemplifies our leadership in technology-driven drug design.”  Learn more: https://lnkd.in/eSmHTQeb   #CDK7 #drugdesign #AI #clinicaltrials #oncology

We’re excited to be working with the Rapidly Emerging Antiviral Drug Development Initiative (READDI), to gather their preclinical drug testing expertise to evaluate and improve a range of AI-designed antiviral compounds for pandemic preparedness.    Read our blog by Professor Ian Goodfellow, Vice President of Antivirals at Exscientia.    #AI #PandemicPreparedness 

Today we announced the expansion of our work with Amazon Web Services (AWS), integrating generative AI drug design and robotic lab automation, to further accelerate our ability to deliver high quality drug candidates at a faster speed and lower cost.     By encoding, automating and integrating the loop of design, synthesis and testing with our generative design workflows in our new AutomationStudio, we’ve taken the next step to increase the speed of learning, and to reduce the time and cost of exploring new therapeutic alternatives. Learn more here: https://lnkd.in/ghT23K7C

Thank you Tanuja Randery for hosting our interim CEO Dave H., in the latest AWS “Conversations with Leaders” podcast.    Hear from Dave and Tanuja on the digital transformation of drug R&D and the role of AI, including Dave’s views of the future of using technology to speed up the design and discovery of novel drug candidates and his vision for Exscientia. Learn how AWS and Exscientia working together can help create new approaches and, one day, may realise novel solutions for the many patients around the world waiting for effective therapies.    Listen: https://lnkd.in/eT9jtmS2   #AI #drugdiscovery #podcast #AWS #AWSConversationsWithLeaders

Thank you Tanuja Randery for hosting our interim CEO Dave H., in the latest AWS “Conversations with Leaders” podcast.    Hear from Dave and Tanuja on the digital transformation of drug R&D and the role of AI, including Dave’s views of the future of using technology to speed up the design and discovery of novel drug candidates and his vision for Exscientia. Learn how AWS and Exscientia working together can help create new approaches and, one day, may realise novel solutions for the many patients around the world waiting for effective therapies.    Listen: https://lnkd.in/eT9jtmS2   #AI #drugdiscovery #podcast #AWS #AWSConversationsWithLeaders

We’re proud to have our interim CEO Dr. Dave H. share Exscientia’s approach to ‘Human-led AI drug discovery’ at the prestigious Milner Therapeutics Symposium, hosted by the University of Cambridge tomorrow (July 2nd).     The use of AI in designing chemical molecules is well established. However, delivering effective, well-tolerated future drugs continues to need a blend of the best human science and tech expertise with the capacity of generative technologies.     By integrating human science, AI-led design and comprehensive process automation across the drug discovery value chain, at Exscientia we aim to further cut down cycle times while improving the quality of drug candidates for clinical development and, ultimately, patients.    We look forward to an inspiring event and compelling insights from expert speakers across several organisations including the University of Cambridge, the Broad Institute, MSD and BioCentury. https://lnkd.in/ew4UBy-V

Don’t miss our webinar tomorrow! Register now to learn how Exscientia is automating structure-based design for kinase hit identification, presented by Chris Radoux.    Register here for the CCDC - The Cambridge Crystallographic Data Centre hosted event: https://lnkd.in/esssSWy5    #AI #Automation #DrugDesign #Webinar 

We’re proud to be awarded the #PrixGalien International 2024 for Best Digital Health Solution, for Exscientia’s end-to-end precision medicine platform. This comes upon having won the UK (2023) and US (2022) national Prix Galien awards in the same category. Thank you to the fantastic team who’ve been driving this important work leading to new insights in AI-enabled, individualised cancer treatment. 

Will AI transform drug discovery? Listen to the WisdomTree podcast on ‘The Next Big Thing: Molecules and Machine Learning’, featuring our CFO Ben Taylor alongside Mobeen Tahir, CFA and Chris Ganetti. They discuss how generative AI can revolutionise the search for novel drugs and Exscientia’s pioneering approach to AI in drug discovery. You tube: https://lnkd.in/d5kZ7Vg5 #drugdiscovery #ai #biotechnology